Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study

Table 6 Comparison of the two treatment groups for osteonecrosis

Item		BGP	IL-17	S100A12	SIP	Cysc	SCr	Hb
Eucommia and meloxicam group	Before treatment	1.95 ± 0.17	142 ± 11.56	65 ± 4.6	0.312 ± 0.06	2.45 ± 0.21	35 ± 5.3	145 ± 6.4
	After treatment	1.64 ± 0.15	125.13 ± 13.84	42.7 ± 4.8	0.124 ± 0.04	1.42 ± 0.17	57 ± 3.5	123 ± 4.6
	t	2.419	1.432	7.924	9.185	8.175	12.513	6.713
	P	0.039	0.186	0.000	0.000	0.000	0.000	0.000
Meloxicam group	Before treatment	0.85 ± 0.13	123 ± 8.5	53 ± 4.7	0.132 ± 0.004	2.13 ± 0.11	68 ± 5.4	132 ± 5.4
	After treatment	0.58 ± 0.21	98.1 ± 12.9	16.38 ± 3.5	0.069 ± 0.005	1.69 ± 0.19	82 ± 3.5	105 ± 4.7
	t	3.723	3.517	14.093	5.506	4.856	5.239	13.069
	P	0.005	0.007	0.000	0.000	0.001	0.001	0.000
Comparison of the two groups before treatment	t	15.74	7.292	3.17	8.95	4.848	10.548	5.745
	P	0.000	0.000	0.011	0.000	0.001	0.000	0.000
Comparison of the two groups after treatment	t	11.959	10.409	9.833	4.25	4.013	12.444	9.21
	P	0.000	0.000	0.000	0.002	0.003	0.000	0.000

BGP: Bone-GLA protein; S100A12: Recombinant human S100 calcium binding protein A12; SIP: Sphingosine 1-phosphate; Cysc: Cystatin C; SCr: Creatinine; Hb: Hemoglobin.